The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells

References

• Adamcová M, Gersl V, Hrdina R, Melka M, Mazurová Y, Vávrová J, Palicka V, Kokstein Z. (1999). Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 125:268–274.
   PubMed Web of Science ®Google Scholar
• Appleyard MV, O’Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. (2009). Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 124:465–472.
   PubMed Web of Science ®Google Scholar
• Ax W, Soldan M, Koch L, Maser E. (2000). Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59:293–300.
   PubMed Web of Science ®Google Scholar
• Bae JY, Ahn SJ, Han W, Noh DY. (2007). Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 101:1038–1045.
   PubMed Web of Science ®Google Scholar
• Carlquist M, Frejd T, Gorwa-Grauslund MF. (2008). Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact 174:98–108.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267–3285.
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer 5:78.
   PubMed Web of Science ®Google Scholar
• Erenpreisa J, Cragg MS. (2001). Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1:1.
   PubMedGoogle Scholar
• Erlund I, Silaste ML, Alfthan G, Rantala M, Kesäniemi YA, Aro A. (2002). Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur J Clin Nutr 56:891–898.
   PubMed Web of Science ®Google Scholar
• Fischer D, Seifert M, Becker S, Ludders D, Cordes T, Reichrath J, Friedrich M. (2007). 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics 4:295–300.
   PubMedGoogle Scholar
• Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M, Skálová L. (2008). Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact 176:9–18.
   PubMed Web of Science ®Google Scholar
• Gersl V, Mazurová Y, Bajgar J, Melka M, Hrdina R, Palicka V. (1996). Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch Toxicol 70:645–651.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Covarrubias V, Kalabus JL, Blanco JG. (2008). Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER). Pharm Res 25:1730–1734.
   PubMed Web of Science ®Google Scholar
• Kaiserová H, Simunek T, van der Vijgh WJ, Bast A, Kvasnicková E. (2007). Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim Biophys Acta 1772:1065–1074.
   PubMed Web of Science ®Google Scholar
• Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113–2120.
   PubMed Web of Science ®Google Scholar
• Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y. (2005). Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res 7:R1097–R1110.
   PubMed Web of Science ®Google Scholar
• Klucar J, Al-Rubeai M. (1997). G2 cell cycle arrest and apoptosis are induced in Burkitt’s lymphoma cells by the anticancer agent oracin. FEBS Lett 400:127–130.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. (2009). Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast 18:218–224.
   PubMed Web of Science ®Google Scholar
• Lewis MJ, Wiebe JP, Heathcote JG. (2004). Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4:27.
   PubMed Web of Science ®Google Scholar
• López de Cerain A, Marín A, Idoate MA, Tuñón MT, Bello J. (1999). Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35:320–324.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. (2003). Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989–998.
   PubMed Web of Science ®Google Scholar
• Ng R, Better N, Green MD. (2006). Anticancer agents and cardiotoxicity. Semin Oncol 33:2–14.
   PubMed Web of Science ®Google Scholar
• O’Connor R, O’Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O’Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. (2007). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol 59:79–87.
   PubMed Web of Science ®Google Scholar
• Oppermann U. (2007). Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293–322.
   PubMed Web of Science ®Google Scholar
• Ravizza R, Gariboldi MB, Molteni R, Monti E. (2008). Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells. Oncol Rep 20:625–630.
   PubMed Web of Science ®Google Scholar
• Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. (2004). Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–191.
   PubMed Web of Science ®Google Scholar
• Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. (2008). Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 10:35–46.
   PubMed Web of Science ®Google Scholar
• Simstein R, Burow M, Parker A, Weldon C, Beckman B. (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 228:995–1003.
   PubMed Web of Science ®Google Scholar
• Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E. (2009a). Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. Toxicology 264:52–60.
   PubMed Web of Science ®Google Scholar
• Skarydová L, Zivná L, Xiong G, Maser E, Wsól V. (2009b). AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact 178:138–144.
   PubMed Web of Science ®Google Scholar
• Tan ML, Choong PF, Dass CR. (2009). Review: doxorubicin delivery systems based on chitosan for cancer therapy. J Pharm Pharmacol 61:131–142.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL. (2005). An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol 3:e128.
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, Tannock IF. (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454.
   PubMed Web of Science ®Google Scholar
• Václavíková R, Kondrová E, Ehrlichová M, Boumendjel A, Kovár J, Stopka P, Soucek P, Gut I. (2008). The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem 16:2034–2042.
   PubMed Web of Science ®Google Scholar
• Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, Cull S, Maclean DA, Parissenti AM. (2009). Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 19:477–488.
   PubMed Web of Science ®Google Scholar
• Zimmermann TJ, Niesen FH, Pilka ES, Knapp S, Oppermann U, Maier ME. (2009). Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. Bioorg Med Chem 17:530–536.
   PubMed Web of Science ®Google Scholar